EMA supports use of dapivirine vaginal ring to prevent HIV in high-incidence countries

Simon Collins, HIV i-Base

On 24 July 2020, the EMA adopted a positive opinion for the safety and efficacy of a dapivirine vaginal ring to be used to protect against HIV.

This was only for use in high incidence countries though, rather than within the EU.

Efficacy data reported a 35% reduction in HIV rates compared to placebo but as with other prevention studies, higher protection was reported with good adherence.

The ring contains 25 mg of dapivirine and lasts for one month.


EMA. Vaginal ring to reduce the risk of HIV infection for women in non-EU countries with high disease burden. (24 July 2020).

This article was originally posted on 25 August 2020.

Links to other websites are current at date of posting but not maintained.